Insmed Inc (INSM)vsPraxis Precision Medicines Inc (PRAX)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PRAX
Praxis Precision Medicines Inc
$311.92
+5.86%
HEALTHCARE · Cap: $8.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 8026% more annual revenue ($606.42M vs $7.46M). PRAX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PRAX
Avoid33
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Safe zone — low bankruptcy risk
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Trading at 9.0x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PRAX
The strongest argument for PRAX centers on Altman Z-Score. Revenue growth of 13.5% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PRAX
The primary concerns for PRAX are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PRAX is a value play — different risk/reward profiles.
PRAX carries more volatility with a beta of 3.01 — expect wider price swings.
PRAX is growing revenue faster at 13.5% — sustainability is the question.
PRAX generates stronger free cash flow (-77M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Praxis Precision Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?